Facebook
Twitter
LinkedIn
ForwardAcute Myeloid Leukemia Patient Management Simulator
Many factors can influence treatment selection for patients with acute myeloid leukemia (AML), including risk stratification, eligibility for treatment induction, and the presence of actionable mutations. The NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®) Acute Myeloid Leukemia have been updated to reflect advances in the management of patients with AML. It is important for clinicians to be aware of new and emerging options in the management of patients with AML so that they can develop individualized treatment plans for newly diagnosed, relapsed, or refractory AML based on the patient and disease characteristics.
The goal of this educational activity is to ensure that members of the interprofessional oncology care team have the knowledge and skills necessary to manage their patients with AML. By working through a series of realistic case scenarios, learners will experience how to manage a variety of AML presentations over time. As they make decisions, they will receive expert corrective mentoring from virtual colleagues until they recognize optimal decision-making patterns.
A follow-up case scenario will be sent to learners approximately 60 days after completion of the first 5 scenarios. This will provide an opportunity for learners to test their competence and knowledge retention. CME/CE/MOC credit will be awarded for completion of the follow-up scenario.
Target Audience
This educational program is designed to meet the educational needs of physicians/oncologists, nurse practitioners, nurses, physician assistants, pharmacists, and other health care professionals who manage patients with AML.
Learning Objectives
Following this activity, participants should be able to:
- Compare and contrast the different treatment strategies associated with the management of patients with newly diagnosed and relapsed/refractory AML.
- Develop individualized treatment plans for patients with newly diagnosed AML based on the patient’s age, risk stratification, eligibility for treatment induction, and actionable mutations.
- Select the appropriate treatment for patients with relapsed/refractory AML based on prior treatment, eligibility for treatment induction, and actionable mutations.
- Apply the current recommendations and key updates in the NCCN Guidelines to optimize the management of patients with AML.
- Evaluate new, emerging, and novel therapeutic agents and treatment strategies and incorporate these into the management of patients with AML.
- Communicate with members of the interprofessional oncology care team to improve collaborative performance in the management of patients with AML.
Daniel A. Pollyea, MD, MS – Dr. Pollyea is Professor of Medicine in the Division of Hematology at the University of Colorado School of Medicine, where he also serves as the Clinical Director of Leukemia Services, Associate Chief of Clinical Affairs, and holds the Robert H. Allen, MD Chair in Hematology Research.
Jessica K. Altman, MD – Dr. Altman is Professor in the Division of Hematology/Oncology at Northwestern University Feinberg School of Medicine. She also serves as Director of the Leukemia Program at Robert H. Lurie Cancer Center of Northwestern University.
NCCN Continuing Education Disclosure Policy
It is the policy of NCCN that all planners, faculty, moderators, authors, reviewers and anyone involved in the planning and delivery of NCCN continuing education activities are expected to disclose ALL financial relationships they have had in the past 24 months with ineligible companies. The ACCME Standards for Integrity and Independence require that individuals who refuse to provide this information will be disqualified from involvement in the planning and implementation of accredited continuing education presented by NCCN. NCCN identifies, mitigates and discloses to learners all relevant financial relationships.
In addition, all content has been reviewed to ensure education promotes safe, effective patient care and does not promote the products or services of an ineligible company. Content, including any presentation of therapeutic options, is fair, balanced, evidence-based, scientifically accurate, and free of commercial bias and marketing.
Definitions
Ineligible Company: An ineligible company is any entity whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients.
Relevant Financial Relationships: Financial relationships of any dollar amount occurring within the past 24 months are defined as relevant if the educational content an individual can control is related to the business lines or products of an ineligible company. There is no minimum financial threshold. We ask for disclosure of ALL financial relationships with ineligible companies, regardless of the amount and regardless of the potential relevance of each relationship to the education.
Faculty Disclaimers
All faculty for this continuing education activity are competent in the subject matter and qualified by experience, training, and/or preparation for the tasks and methods of delivery.
Faculty presentations may include discussion of off-label use. Faculty will disclose that the use in question is not currently approved by the FDA per the product labeling or marketing.
Faculty Disclosures
The faculty listed below have the following relevant financial relationships with ineligible companies to disclose. All of the relevant financial relationships listed for these individuals have been mitigated.
Jessica K. Altman, MD
AbbVie, Inc.: Consulting Fee
Astellas Pharma US, Inc.: Consulting Fee
bluebird bio, Inc.: Consulting Fee
Curio Science: Consulting Fee
Gilead Sciences, Inc.: Consulting Fee
GlycoMimetics, Inc.: Consulting Fee
Kura Oncology, Inc.: Consulting Fee
Kymera Therapeutics: Consulting Fee
Stemline Therapeutics, Inc.: Consulting Fee
Syros Pharmaceuticals: Consulting Fee
Daniel A. Pollyea, MD, MS
AbbVie, Inc.: Grant/Research Support; Scientific Advisor
Arcellx: Scientific Advisor
AstraZeneca Pharmaceuticals LP: Scientific Advisor
BeiGene: Scientific Advisor
BerGenBio ASA: Scientific Advisor
Bristol-Myers Squibb Company: Grant/Research Support; Scientific Advisor
Genentech, Inc.: Scientific Advisor
Gilead Sciences, Inc.: Scientific Advisor
HiberCell Inc.: Scientific Advisor
ImmunoGen, Inc.: Scientific Advisor
Jazz Pharmaceuticals Inc.: Scientific Advisor
Karyopharm Therapeutics: Grant/Research Support; Scientific Advisor
Kura Oncology, Inc.: Scientific Advisor
Magenta Therapeutics: Scientific Advisor
Medivir AB: Scientific Advisor
Novartis Pharmaceuticals Corporation: Scientific Advisor
Qihan Biotech: Scientific Advisor
Ryvu Therapeutics: Scientific Advisor
Syndax Pharmaceuticals Inc.: Scientific Advisor
Syros Pharmaceuticals: Scientific Advisor
Teva Pharmaceutical Industries Ltd: Grant/Research Support
Zentalis Pharmaceuticals: Scientific Advisor
NCCN and Syandus Staff Disclosures
The planner listed below has the following relevant financial relationship(s) with ineligible companies to disclose. All of the relevant financial relationships listed for these individuals have been mitigated.
Douglas Seifert, PhD
Merck & Co., Inc.: Consulting Fee
None of the other planners for this educational activity have relevant financial relationship(s) to disclose with ineligible companies whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients.
In support of improving patient care, this activity has been planned and implemented by the National Comprehensive Cancer Network (NCCN) and Syandus. NCCN is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.
Physicians
NCCN designates this enduring material for a maximum of 2.5 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Nurses
NCCN designates this educational activity for a maximum of 2.5 contact hours.
Pharmacists
NCCN designates this application-based continuing education activity for 2.5 contact hours (0.25 CEUs) of continuing education credit. UAN: JA4008196-9999-23-026-H01-P
Physician Assistants
NCCN has been authorized by the American Academy of PAs (AAPA) to award AAPA Category 1 CME credit for activities planned in accordance with AAPA CME Criteria. This activity is designated for 2.5 AAPA Category 1 CME credits. Approval is valid until August 9, 2024. PAs should only claim credit commensurate with the extent of their participation.
American Board of Internal Medicine Maintenance of Certification (MOC)
Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 2.5 MOC points in the American Board of Internal Medicine’s (ABIM) Maintenance of Certification (MOC) program. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.
Aggregated participant data will be shared with the commercial supporters of this activity.
American Board of Pathology Continuing Certification (CC)
This activity has been registered to offer credit in the American Board of Pathology’s (ABPath) Continuing Certification program. Participants may earn up to 2.5 Lifelong Learning (Part II) credits.
Aggregated participant data will be shared with the commercial supporters of this activity.
Price
Method of Participation to Earn Credit
- Participants must review all activity information, including the pre-test, learning objectives, faculty disclosure information, simulation scenario(s) and post-activity evaluation.
- To view the first simulation scenario, launch the simulation with the Take Course button above using a PC, Mac, Tablet, or Phone with a 4G or higher internet connection.
- Interact appropriately to satisfy each objective to unlock the next objective and view the next simulation scenario.
- The simulation will track your progress until all scenario objectives are complete.
- Exit the simulation at any time, and your progress will be saved so you can return to finish at a later time.
- As you complete each scenario (1 minimum, 5 total), you will qualify for increasing levels of CE credit (ranging from 0.5 to 2.0 credits). Click or tap "Credit" to determine your CE credit status.
- An additional 0.5 credit is available to those who complete the second module.
- Upon successful completion of the evaluation, you can download/print a certificate of credit immediately via the browser.
Fee Information
There is no fee to participate in this activity.
Contact Information
For further information about this activity, contact education@nccn.org; for technical support for this activity, contact support@alivesim.com.
Privacy and Confidentiality
NCCN and Syandus respect the privacy and confidentiality of users of this activity. The privacy statement for this activity is available from within the activity and by clicking here.
Copyright Statement
This CME simulation activity is licensed to National Comprehensive Cancer Network (NCCN). Copyright © 2023 Syandus Inc and NCCN. All rights reserved. No part of this simulation activity may be reproduced without written permission from NCCN and Syandus Inc.
Required Hardware/software
Any modern phone or tablet with at least 2GB of RAM (typically 3-4 years old or newer), or a PC/Mac that is 5 years old or newer. A good user experience requires a broadband connection of 4G or better via a modern web browser (Chrome, Firefox, Safari, or Edge; Internet Explorer is not supported).